Key Highlights

  • IDEXX reported Revenue rising around 10% in one quarter of 2026, with strong companion-animal diagnostics growth.
  • The company raised its full-year outlook following the results.
  • Its razor-and-blade model sells diagnostic analysers to vet practices, then earns Recurring Revenue from consumable tests.
  • Growing pet ownership and rising willingness to spend on veterinary care support durable long-term demand.

IDEXX Laboratories (NASDAQ:IDXX) has built a highly profitable Business out of a simple trend: people increasingly treat their pets as family and spend accordingly on their health. As the leader in veterinary diagnostics, IDEXX makes pet testing a distinctive and durable growth theme within the Nasdaq 100.

What IDEXX Does

IDEXX Laboratories is the leading provider of diagnostic products and services for veterinary practices, helping vets test animals for diseases and monitor their health. It sits in the healthcare sector. It sells the analysers that sit in vets' offices, the consumable tests and cartridges those machines use, and reference-laboratory services for more complex testing, along with software to run veterinary practices. Much of its revenue is recurring, coming from the steady stream of consumable tests that its installed base of analysers requires.

Recurring Growth From Pet Health

IDEXX has delivered consistent growth. In 2026 it reported revenue rising at a healthy pace, up around 10 per cent in one quarter, with its core companion-animal diagnostics generating strong, recurring revenue growth, and it raised its full-year outlook. The business benefits from powerful long-term trends: pet ownership has grown, and owners are increasingly willing to spend on advanced veterinary care, including diagnostics. Because IDEXX places analysers in vets' practices and then sells the consumable tests they use, it enjoys a razor-and-blade model, earning steady, high-margin revenue from testing long after the initial equipment sale, which gives it durable, recurring growth.

Why it Matters for the Nasdaq 100

IDEXX offers the index exposure to the resilient and growing market for pet health, a distinctive theme separate from the technology and consumer names that dominate. Its results are a useful read on how much owners are spending on their pets, spending that has proved relatively resilient. As a highly profitable member of the benchmark with sticky, recurring revenue, it provides a blend of steady growth and quality, and its performance reflects the durable trend of the humanisation of pets.

The Razor-and-blade Model

IDEXX's business model deserves particular attention, because it underpins its quality. By placing diagnostic analysers in veterinary practices, often at attractive terms, IDEXX builds an installed base that then generates a long, recurring stream of revenue from the consumable tests those machines require. This razor-and-blade approach creates high switching costs: once a practice adopts IDEXX's equipment and workflow, and its staff are trained on it, moving to a rival is disruptive, so customers tend to stay. The recurring test revenue is high-margin and grows as vets run more diagnostics, which they increasingly do as veterinary medicine advances. This combination of a growing installed base, sticky customers and recurring, high-margin consumables is what makes IDEXX such a high-quality business, and it is why the shares command a premium valuation more common among technology companies than diagnostics firms.

The Risks to Weigh

IDEXX's valuation is high, so any slowdown in growth can weigh on the shares. Pet-care spending, while resilient, is not immune to a severe downturn. Competition in veterinary diagnostics is significant. Veterinary-visit trends can soften, affecting testing volumes. The pace of new-product development requires continued investment. Any pressure on the number of vet visits, which has fluctuated, would affect Demand for its tests.

The Business Behind a Beloved Pet's Checkup

Readers should track recurring companion-animal diagnostics revenue, the high-margin heart of the business, and watch trends in veterinary visits, which drive testing volumes. The Placement of new analysers indicates future consumable revenue. Commentary on pet-care spending reveals the backdrop. New-product launches, including advanced tests, show innovation. Margins reveal profitability. Finally, watch veterinary-visit trends, because IDEXX's growth ultimately depends on pets being brought to the vet and tested, the activity that generates the recurring revenue on which its high-quality model rests. Any softening in vet-visit frequency would be an early signal worth heeding.